Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Restless Legs Syndrome
Interventions
DRUG

Rotigotine

"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"

OTHER

Placebo

"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"

Trial Locations (18)

Unknown

006, Birmingham

013, Jasper

021, Gilbert

014, Little Rock

010, Oceanside

004, Orange

002, Tampa

012, Macon

008, Destrehan

017, Brighton

016, Brockton

019, Kalamazoo

015, St Louis

007, West Seneca

018, Cincinnati

009, West Chester

003, Austin

005, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT01569464 - Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) | Biotech Hunter | Biotech Hunter